Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmutepIMMP +12.98%23 Price-to-Tangible-Book is 1.30 as of Sep. 12, 2026. GuruFocus rates IMMP with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, Immutep ranks better than 85.09% on this metric.
As of today (2026-09-12), Immutep's share price is $0.3707. Immutep's Tangible Book per Share of Jun. 2026 for the quarter that ended in Jun. 2026 was $0.29. Hence, Immutep's Price to Tangible Book Ratio of today is 1.30.
The historical rank and industry rank for Immutep's Price-to-Tangible-Book or its related term are showing as below:
IMMP'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.29 Med: 3.61 Max: 11.53
Current: 1.43
During the past 13 years, Immutep's highest Price to Tangible Book Ratio was 11.53. The lowest was 1.29. And the median was 3.61.
IMMP's Price-to-Tangible-Book is ranked better than 85.09% of 1127
companies
in the Biotechnology industry
Industry Median: 3.27
vs IMMP: 1.43
A closely related ratio is called PB Ratio. As of today, Immutep's share price is $0.3707. Immutep's Book Value per Sharefor the quarter that ended in Jun. 2026 was $0.29. Hence, Immutep's P/B Ratio of today is 1.27.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Immutep Price-to-Tangible-Book Related Terms
Immutep Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Immutep's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMMP vs VRTX, REGN, MRNA: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Immutep's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immutep Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immutep's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Immutep's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Immutep (IMMP) has a Price-to-Tangible-Book of 1.30 as of Sep. 12, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Immutep and its competitors. According to the industry distribution chart, Immutep ranks #168 out of 1127 companies in the Biotechnology industry, placing it in the top 14.9%.
Is Immutep's Price-to-Tangible-Book too high?
Immutep's current Price-to-Tangible-Book is 1.30. The Biotechnology industry median Price-to-Tangible-Book is 3.27. Immutep's value of 1.30 is 60.2% below this industry median. Based on the distribution chart, Immutep ranks #168 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immutep has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Immutep's Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immutep ranks #168 out of 1127 companies for Price-to-Tangible-Book. This places Immutep in the top 15% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 3.27. Immutep's value of 1.30 is 60.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.27, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immutep's current Price-to-Tangible-Book of 1.30 is 60.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Immutep and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immutep's current Price-to-Tangible-Book is 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immutep stock overvalued right now?
Immutep (IMMP) has a current Price-to-Tangible-Book of 1.30. The current Price-to-Tangible-Book is 1.30 and 60.2% below the Biotechnology industry median of 3.27. Immutep's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Immutep (IMMP), the current Price-to-Tangible-Book is 1.30 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
23GF Score
Get the complete analysis for IMMP
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMMP has been successfully added to your 
